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Ptorvastatin Increases Plasma Soluble
ms-Like Tyrosine Kinase-1 and Decreases
ascular Endothelial Growth Factor and Placental
rowth Factor in Association With Improvement of
entricular Function in Acute Myocardial Infarction
asushi Kodama, MD, Yoshinobu Kitta, MD, Takamitsu Nakamura, MD, Hajime Takano, MD, PHD,
en Umetani, MD, PHD, Daisuke Fujioka, MD, Yukio Saito, MD, Ken-ichi Kawabata, MD,
yun-ei Obata, MD, PHD, Akira Mende, MD, Tsuyoshi Kobayashi, MD, Kiyotaka Kugiyama, MD, PHD
amanashi, Japan
OBJECTIVES This study examined whether atorvastatin increases plasma levels of soluble Fms-like tyrosine
kinase 1 (sFlt-1) and reciprocally decreases vascular endothelial growth factor (VEGF) and
placental growth factor (PlGF) levels in patients with acute myocardial infarction (AMI).
BACKGROUND Statins exert cardioprotective actions partly through anti-inflammatory actions. By capturing
VEGF and PlGF in plasma, sFlt-1 acts as a natural inhibitor of VEGF and PlGF, which have
proinflammatory properties.
METHODS Left ventriculography and enzyme-linked immunosorbent assay of plasma levels of sFlt-1,
VEGF, and PlGF were repeated after AMI in 50 consecutive patients with a first AMI.
Patients were randomized to treatment with atorvastatin (10 mg/day; n  25) or placebo
(n  25) within 3 days after AMI, and therapy was continued for 6 months.
RESULTS The sFlt-1 levels were low in the acute phase, followed by an increase at 2 weeks after AMI,
whereas free VEGF and PlGF levels were high in the acute phase, followed by a decrease at
2 weeks. Atorvastatin increased sFlt-1 levels and reciprocally decreased VEGF and PlGF
levels at 6 months compared with placebo. The increase in sFlt-1 levels and the decrease in
VEGF and PlGF levels were correlated with improvement of left ventricular ejection fraction
during the follow-up period.
CONCLUSIONS There was a reciprocal relationship between changes in sFlt-1 levels and changes in VEGF
and PlGF levels after AMI; and atorvastatin increased sFlt-1 levels while decreasing VEGF
and PlGF levels. These changes were associated with late improvement of post-MI
ventricular function, and may represent an additional benefit of statin therapy. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.035Cardiol 2006;48:43–50) © 2006 by the American College of Cardiology Foundation
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ohe Fms-like tyrosine kinase 1 (Flt-1), a receptor for vascular
ndothelial growth factor (VEGF) and placental growth factor
PlGF), can also be produced as a soluble protein (sFlt-1)
hich lacks both the membrane-spanning and intracellular
yrosine kinase domains of Flt-1 (1–4). Soluble Flt-1 is
enerated by alternative splicing of the Flt-1 gene in vascular
ndothelium as well as placenta (4,5). Soluble Flt-1 captures
EGF and PlGF in plasma and reduces the amount of free
EGF and PlGF available to bind to their vascular endothelial
eceptors (4–7). Therefore, sFlt-1 levels could potentially
etermine the free plasma levels of VEGF and PlGF and their
athophysiologic activities (4–11).
It has been shown that the exogenous administration of
EGF and PlGF was effective in causing therapeutic
ngiogenesis in animal models and in patients with coronary
rtery disease (CAD) (12,13). However, Flt-1, a receptor
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echnology, Health, and Labor Sciences Research Grants for Comprehensive
esearch on Aging and Health (H15-Choju-012), Tokyo, Japan.b
Manuscript received January 6, 2006; revised manuscript received February 22,
006, accepted March 6, 2006.or VEGF and PlGF, is expressed on monocytes/macrophages
s well as vascular endothelium (1–3). Thus, VEGF and PlGF
lso have proinflammatory properties and promote monocyte
ctivation and migration through Flt-1 (1–3). In this context,
EGF and PlGF have proatherogenic activity as well as
ntiatherogenic activity; therefore, the role of the endogenous
EGF and PlGF in the long-term clinical outcome of CAD
emains unclear. In fact, elevated levels of endogenous VEGF
r PlGF were associated with an adverse prognosis in patients
ith acute coronary syndrome (ACS) (14,15). Therefore, levels
f sFlt-1, a natural antagonist of VEGF and PlGF, may also
rovide important prognostic information in ACS. A previous
eport (9) showed that plasma sFlt-1 levels were decreased
ithin 24 h after thrombolytic therapy in patients with acute
yocardial infarction (AMI), but sFlt-1 levels were not mea-
ured over several months and there was no assessment of the
linical significance of the sFlt-1 changes.
Statins are shown to exert beneficial effects on the clinical
utcome of ACS partly through anti-inflammatory actions in
ddition to their lipid-lowering effects (16,17). A previous
tudy (18) showed that atorvastatin decreased the plasma levels
f free VEGF in patients with CAD in the absence of AMI,
ut the study did not examine sFlt-1 levels and the possible
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Soluble Flt-1 and Statin in Myocardial Infarction July 4, 2006:43–50linical significance of the decrease in VEGF levels. Therefore,
e hypothesized that statin treatment may affect serial changes
n the plasma levels of sFlt-1, VEGF, and PlGF over the time
ourse of AMI, leading to an improvement of the depressed
ardiac function that occurs after AMI. In this study, we
etermined the effect of atorvastatin on plasma levels of sFlt-1,
EGF, and PlGF over 6 months in patients with AMI and
xamined the relation between changes in the plasma levels of
hese factors with post-MI left ventricular function.
ETHODS
tudy patients. This study included 50 consecutive patients
ith a first AMI who were admitted within 24 h after the
nset of symptoms and had successful reperfusion therapy
Table 1. Patients’ Characteristics at Baseline
Acute Myocar
Atorvastatin
(n  25)
Age (yrs) 64.5  2.1
Male (%) 68
BMI (kg/m2) 23.2  0.6
Smoking (%) 56
Hypertension (%) 72
Diabetes mellitus (%) 60
Total cholesterol (mg/dl) 196  8
Triglyceride (mg/dl) 133  17
HDL cholesterol (mg/dl) 46  3
LDL cholesterol (mg/dl) 120  6
Location of MI (%)
Anterior 52
Inferior 28
Others 20
Extent of CAD (%)
1-vessel 36
2-vessel 40
3-vessel 24
Killip classification (%)
Class I 72
Class II to IV 28
Peak CK-MB (ng/ml) 266  45
Time to reperfusion (h) 6.4  0.9
Values represent the percent of the patients and control subjec
for 10 years; hypertension defined as 140/90 mm Hg
according to the American Diabetes Association report or a
Abbreviations and Acronyms
ACS  acute coronary syndrome
AMI  acute myocardial infarction
CAD  coronary artery disease
Flt-1  Fms-like tyrosine kinase 1
LDL  low-density lipoprotein
LVEDVI  left ventricular end-diastolic volume index
LVEF  left ventricular ejection fraction
LVESVI  left ventricular end-systolic volume index
MI  myocardial infarction
PlGF  placental growth factor
VEGF  vascular endothelial growth factorBMI  body mass index; CAD  coronary artery disease; CK
 low-density lipoprotein; MI  myocardial infarction.ith percutaneous coronary intervention immediately after
dmission to Yamanashi University Hospital. The diagnosis
f AMI was made on the basis of chest pain persisting for
30 min, ST-segment elevation of 0.2 mV in 2
ontiguous leads on a standard 12-lead electrocardiogram,
nd elevation of serum creatine kinase levels to more than
wice the upper limit of normal. The study excluded patients
ith total cholesterol levels of 240 mg/dl or use of
ipid-lowering medications at admission. The study also
ncluded 20 control subjects selected from the consecutive
7 subjects with angiographically normal coronary arteries
nd a normal left ventriculogram who underwent cardiac
atheterization at Yamanashi University Hospital during
he same study periods as patients with AMI. They were
elected to match the AMI patients for atherosclerosis risk
actors, and plasma levels of sFlt-1, VEGF, and PlGF were
ompared between the AMI patients and control subjects.
he clinical characteristics of the patients with AMI and
he control subjects are shown in Table 1. Written informed
onsent was obtained from all patients and control subjects
efore the study. The study was in agreement with the
uidelines approved by the ethics committee at our
nstitution.
tudy protocol and blood sampling. The patients with
MI were randomly assigned to receive 6 months of oral
torvastatin (10 mg/day) or placebo (similar-appearing tab-
et) using a random number table generated by a computer.
nfarction
Placebo
(n  25)
Controls
(n  20) p Value
62.7  2.2 64.1  1.1 NS
72 75 NS
24.5  0.6 24.5  0.6 NS
48 55 NS
64 70 NS
64 55 NS
202  8 198  5 NS
143  12 124  8 NS
45  3 49  2 NS
116  7 115  4 NS
56 — NS
20 — NS
24 — NS
48 — NS
32 — NS
20 — NS
64 — NS
36 — NS
294  77 — NS
6.1  0.8 — NS
ean SE. Smoking defined as smoking10 cigarettes/day
of antihypertensive medication; diabetes mellitus defined
g an antidiabetic medication.dial I
ts or m
or use
s takin creatine kinase; HDL  high-density lipoprotein; LDL
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July 4, 2006:43–50 Soluble Flt-1 and Statin in Myocardial Infarctionll patients were blinded to the content of the tablets. The
reatment was started within 3 days after admission. All
atients received instruction and counseling to promote
ompliance with lipid-lowering diet according to the Na-
ional Cholesterol Education Program Adult Treatment
anel III guideline. Patients were not permitted to be
reated with any lipid-modifying drugs other than the study
rug.
At the acute phase of MI, blood samples were obtained
rom an antecubital vein without stasis in all patients
mmediately after admission and before the administration
f heparin. In 32 patients with AMI admitted within 6 h
fter symptom onset, blood samples were taken every 4 h
ver the first 24 h for determination of creatine kinase levels.
urthermore, blood samples were taken at 2 weeks and 6
onths after AMI in the same manner from the antecubital
ein without stasis in all patients with AMI. In the control
ubjects, blood samples were obtained from the antecubital
ein without stasis. The blood samples, anticoagulated with
DTA, were immediately centrifuged at 3,000 rpm for 10
in at 4°C, and an aliquot of the EDTA-plasma was stored
t 80°C until analyzed. Serum from a peripheral vein was
lso obtained at the same time.
ssays. Plasma levels of sFlt-1 were measured by enzyme-
inked immunosorbent assay (ELISA) (R&D Systems,
inneapolis, Minnesota) according to the manufacturer’s
nstruction. The sFlt-1 ELISA system is capable of detect-
ng the total amount of plasma sFlt-1, including that bound
o VEGF and PlGF. Plasma levels of free VEGF and PlGF
not bound to sFlt-1) were measured by sandwich ELISAs
R&D Systems) (5,11,19). Both free and sFlt-1–bound
EGF levels (total VEGF levels) were measured by com-
etitive immunoassay (Accucyte; Cytimmune Science,
ockville, Maryland) (19,20). The minimal detection limits
or sFlt-1, free VEGF, free PlGF, and total VEGF levels
ere 14.4 pg/ml, 9 pg/ml, 7 pg/ml, and 0.195 ng/ml,
espectively. The C-reactive protein levels in the serum were
ssayed by rate nephelometry (Dade Behring, Marburg,
ermany). Plasma levels of interleukin-8 were measured by
LISA (Quantikine; R&D Systems). These assays were
erformed by an investigator blinded to the sources of the
amples.
ardiac catheterization. Cardiac catheterization was per-
ormed immediately after admission at the acute phase of
MI and at 2 weeks and 6 months after AMI in all patients
ith AMI. Left ventriculography was performed at 2 weeks
nd 6 months after AMI. Left ventricular ejection fraction
LVEF), left ventricular end-diastolic volume index
LVEDVI), and left ventricular end-systolic volume in-
ex (LVESVI) were determined with left ventriculo-
rams by area-length methods using computer-assisted
nalysis (Cardio 2000; Fukuda-denshi Corp., Tokyo,
apan).
tatistical analysis. Data are expressed as mean  SEM
nless otherwise indicated. The mean value and frequency
etween two groups were compared using Student unpaired atest and chi-squared test, respectively. When frequencies
mong the patients with atorvastatin treatment, patients
ith placebo, and control subjects were compared (Table 1),
hi-squared test using a 2  3 contingency table was
nitially examined for independence of frequencies among
he three groups. When significant in independence by
hi-square test, wholly significant difference was calculated
Tukey test) between the two groups. One-way analysis of
ariance followed by a Scheffe test for post hoc comparisons
as used for comparisons of mean values before and during
he treatment and of mean values among the three patient
roups. The mean values of lipid and other biochemical
arameters and of cardiac function before and during
reatment in the two AMI groups were compared using
wo-way analysis of variance for repeated measures followed
y post-hoc testing with a Scheffe test. The relationships of
Flt-1, VEGF, and PlGF levels, ventricular function, and
ther parameters was examined by linear regression analysis.
tatistical significance was defined as p  0.05. Analyses
ere performed in part using StatView 5.0 for Windows
Tokyo, Japan).
ESULTS
omparisons of baseline clinical characteristics. The
tudy patients with AMI were randomly assigned to ator-
astatin treatment in 25 patients and placebo in 25 patients.
ll of the study patients completed the trial. The clinical
haracteristics of the patients with AMI and the control
ubjects are shown in Table 1. Risk factor profiles were
imilar among the two treatment groups and the control
ubjects, as shown in Table 1. Clinical parameters associated
ith AMI were comparable between the two treatment
roups with AMI, as shown in Table 1.
In the acute phase of MI (within 24 h after AMI), sFlt-1
lasma levels were lower in patients with AMI than in
ontrol subjects, whereas free VEGF and PlGF levels were
igher, as shown in Figures 1A to 1C. The placebo- and
torvastatin-treated groups with AMI had comparable lev-
ls of sFlt-1, free VEGF, and free PlGF in the acute phase
f MI, as shown in Figures 1A to 1C.
ffects of treatments with atorvastatin and placebo dur-
ng the follow-up period in patients with AMI. The
ffects of the treatments on lipid profiles, cardiac function,
nd other clinical features are shown in Table 2. The levels
f total cholesterol and low-density lipoprotein (LDL)
holesterol were significantly lower in the atorvastatin group
han in the placebo group at 6 months after AMI, but the
evels were comparable between the two treatment groups
t 2 weeks after AMI. The frequencies of each of the
ardiac medications were similar except for atorvastatin
etween the two treatment groups during the follow-up
eriod.
Plasma levels of sFlt-1, free VEGF, and free PlGF were
ot significantly different among the two treatment groups
nd the control subjects at 2 weeks after AMI, as shown in
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Soluble Flt-1 and Statin in Myocardial Infarction July 4, 2006:43–50igures 1A to 1C. The plasma levels of sFlt-1, free VEGF,
nd free PlGF were unchanged from 2 weeks to 6 months
fter AMI in the placebo group. However, in the atorva-
tatin group, sFlt-1 levels increased from 2 weeks to 6
onths after AMI, whereas free VEGF and free PlGF
evels reciprocally decreased from 2 weeks to 6 months after
MI, as shown in Figures 1A to 1C. Total VEGF levels
ad similar changes during the study period as free VEGF
evels (Fig. 1D). However, there was no significant differ-
nce in total VEGF levels between the two treatment
roups (Fig. 1D). As shown in Figure 2, the relative changes
n the plasma levels at 2 weeks and 6 months after AMI to
he levels at acute phase of MI (100) between the two
reatment groups remained similar between the two
reatment groups to the absolute changes shown in the
igure 1.
The LVEF in the atorvastatin group was similar at 2
eeks after AMI but significantly greater at 6 months after
MI compared with the placebo group, as shown in
igure 3 and Table 2. The LVEDVI and LVESVI in the
torvastatin group showed a tendency to be lower at 6
onths after AMI than in the placebo group, but not
igure 1. Comparison of soluble Fms-like tyrosine kinase-1 (sFlt-1) (A), f
PlGF) (C), and total VEGF (D) levels during the follow-up period after
.05 vs. respective levels in the acute phase of myocardial infarction. †p eaching significance, as shown in Table 2. aorrelation of changes in levels of sFlt-1, VEGF, or
lGF and ventricular function during the treatment in
atients with AMI. The percentage changes in LVEF
ere correlated positively with the percentage changes in
Flt-1 levels and inversely with the percentage changes in
ree VEGF and free PlGF levels from 2 weeks to 6 months
fter AMI, as shown in Figure 4.
The percentage changes in interleukin-8 levels were
ignificantly correlated positively with percentage changes in
ree VEGF and free PlGF levels and inversely with sFlt-1
evels from 2 weeks to 6 months (r 0.31, 0.35, and0.29,
espectively; all p  0.05). The percentage changes in LDL
holesterol and C-reactive protein levels did not show a
ignificant correlation with percentage changes in sFlt-1,
ree VEGF, and free PlGF levels and LVEF from 2 weeks
o 6 months after AMI (LDL cholesterol levels: r  0.1,
.1, 0.05, and 0.14, respectively; C-reactive protein levels:
 0.15, 0.19, 0.2, and 0.05, respectively).
ISCUSSION
he present study showed that sFlt-1 levels were elevated
scular endothelial growth factor (VEGF) (B), free placental growth factor
in patients treated with atorvastatin (n  25) and placebo (n  25). *p 
vs. healthy control subjects.ree vand free VEGF and free PlGF levels were reciprocally
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July 4, 2006:43–50 Soluble Flt-1 and Statin in Myocardial Infarctionecreased at the acute phase of MI compared with healthy
ontrol subjects. Furthermore, by 2 weeks after MI in both
he atorvastatin and placebo groups, these levels returned to
evels similar to those obtained in healthy control subjects.
he elevation of VEGF and PlGF levels at the acute phase
f MI may be an adaptive mechanism for inducing neovas-
ularization in ischemic myocardium (1–3,21,22) and may
e caused in part through a mechanism involving hypoxia-
nducible factor 1 activation (23). The decreased levels of
Flt-1, a natural antagonist of VEGF and PlGF, may be
elpful for the angiogenic activity of VEGF and PlGF in
schemic myocardium in the acute phase of MI. Further-
ore, the present study showed that atorvastatin treatment
nduced an increase in sFlt-1 levels and a reciprocal decrease
n free VEGF and free PlGF levels at 6 months after MI
ompared with placebo treatment. Moreover, these changes
n plasma levels were correlated with improvement of
ost-MI ventricular dysfunction from 2 weeks to 6 months
fter AMI. Change in LDL cholesterol levels was not
elated to the improvement of LV function and changes
n sFlt-1, free VEGF, and free PlGF levels from 2 weeks
o 6 months after AMI. Therefore, it is suggested that
he increase in sFlt-1 levels and the reciprocal decrease in
ree VEGF and free PlGF levels after atorvastatin treat-
ent may have clinical benefit in the chronic phase of MI
Table 2. Risk Factors, Cardiac Functions, and
Patients With Acute Myocardial Infarction
Atorvast
2 Weeks
Risk factors
Total cholesterol (mg/ml) 201  8
LDL cholesterol (mg/ml) 130  6
HDL cholesterol (mg/ml) 49  3
Triglyceride (mg/ml) 134  15
HbA1c (%) 6.2  0.3
Systolic BP (mmHg) 129  6
CRP (mg/ml) 0.80  0.26
IL-8 (pg/ml) 77.9  3.1†
BMI (kg/m2) 22.8  0.5
Cardiac function
LVEF (%) 54.3  2.3
LVEDVI (ml/m2) 94.2  3.3
LVESVI (ml/m2) 41.2  4.4
LVEDP (mmHg) 13.1  0.9
CI (l/min/m2) 2.9  0.1
Medication
ACE-I (%) 76
ARB (%) 24
Beta-blocker (%) 20
Calcium-channel-blocker (%) 36
Aspirin (%) 100
Ticlopidine (%) 76
SU (%) 8
Insulin (%) 12
Values represent the percent of the patients or mean  SE.
ACEI  angiotensin-converting enzyme inhibitor; AR
CI  cardiac index; CRP  C-reactive protein; IL  interle
 left ventricular end-diastolic volume index; LVEF  left v
volume index; SU  sulfonylureas; other abbreviations as inn patients with AMI independently of decrease in lipid tevels. However, the effect of atorvastatin-induced
hanges in plasma levels of sFlt-1, free VEGF, and free
lGF on long-term clinical outcome remains to be
etermined.
Also, the present study showed that total VEGF levels
both free and sFlt-1–bound VEGF levels) had similar
hanges during the study period as free VEGF levels.
owever, atorvastatin treatment did not affect total
EGF levels. These results indicate that atorvastatin
reatment was unlikely to influence the circulating total
EGF levels which may reflect production and degrada-
ion of VEGF in the circulation. Therefore, it is possible
hat atorvastatin treatment may primarily increase sFlt-1
evels, resulting in a decrease in free VEGF levels,
lthough it can not be excluded that atorvastatin could
lter the binding ability of VEGF to acceptors, including
Flt-1, in the circulation.
Vascular endothelial growth factor and PlGF belong to
he same gene family and play a synergistic role in patho-
ogic angiogenesis (1–3,22). Vascular endothelial growth
actor exerts its biologic activities by interacting with two
eceptors, Flt-1 and Flk-1/KDR, whereas PlGF interacts
ith Flt-1 but not Flk-1/KDR (1–4,6,7,22). It has been
hown that Flk-1/KDR, expressed on vascular endothelium,
ainly mediates VEGF-induced angiogenesis (1–3,22). On
ications During the Follow-Up Period in
n  25) Placebo (n  25)
6 Months 2 Weeks 6 Months
166  8*† 209  8 201  8
87  8*† 122  7 116  7
54  3 46  3 50  3
117  13 139  12 133  21
6.0  0.2 6.2  0.2 6.0  0.2
124  5 123  4 126  4
0.11  0.05* 0.74  0.20 0.16  0.03*
77.6  3.5 91.8  5.0 76.7  5.9*
23.0  0.6 23.5  0.5 24.4  0.6
63.5  2.7*† 53.5  2.0 55.2  2.6
93.0  3.1 95.8  4.9 99.1  3.5
34.0  4.3 42.3  4.7 43.5  6.3
13.8  0.9 14.3  1.5 14.0  0.7
3.0  0.1 2.8  0.7 2.8  0.1
64 64 52
32 36 40
16 12 8
44 32 40
96 100 100
20* 72 20*
8 8 12
12 8 8
0.05 vs. 2 weeks; †p  0.05 vs. placebo.
angiotensin II receptor blocker; BP  blood pressure;
LVEDP  left ventricular end-diastolic pressure; LVEDVI
lar ejection fraction; LVESVI  left ventricular end-systolic
1.Med
atin (
*p 
B 
ukin;he other hand, Flt-1 is expressed on endothelial cells and
i
(
t
p
b
V
H
P
F
i
a
w
c
k
s
a
i
i
i
t
r
p
e
u
F
V
F
b
T
o
A
F
F
w
a
m
r
48 Kodama et al. JACC Vol. 48, No. 1, 2006
Soluble Flt-1 and Statin in Myocardial Infarction July 4, 2006:43–50nflammatory cells, namely, monocytes and macrophages
1–3,22). Thus, VEGF and PlGF also have proinflamma-
ory properties, and they both thereby have the capability of
romoting atherosclerosis through Flt-1. This is supported
y previous reports (14,15) showing that elevated levels of
igure 2. Comparisons of the percentage changes in the plasma levels at 2
eeks and 6 months after acute myocardial infarction relative to the levels
t acute phase of myocardial infarction (100%) between the two treat-
ent groups. (A) sFlt-1; (B) free VEGF; (C) free PlGF. †p  0.05 vs.
espective levels at 2 weeks after MI. Abbreviations as in Figure 1.EGF and PlGF in ACS resulted in an adverse prognosis.
(
powever, it remains unclear whether elevated VEGF and
lGF levels in ACS function as a proatherogenic factor via
lt-1 or only serve as a surrogate marker of myocardial
njury. Furthermore, the present study showed that percent-
ge changes in free VEGF, free PlGF, and sFlt-1 levels
ere significantly correlated with the percentage changes in
irculating levels of interleukin-8, a proinflammatory cyto-
ine. It is reported (1–3,24,25) that VEGF and PlGF
timulate various inflammatory cells, including monocytes
nd endothelial cells, leading to production and release of
nterleukin-8 and other proinflammatory molecules. Also, it
s known that these inflammatory cytokines locally produced
n post-infarct myocardium could depress ventricular func-
ions (26,27). Thus, the present results support previous
eports (1–3,14,15) showing that VEGF and PlGF exert as
roinflammatory factors, and these proinflammatory prop-
rties of VEGF and PlGF may influence post-MI ventric-
lar function.
Soluble Flt-1, generated by alternative splicing of the
lt-1 gene, reduces effective plasma concentrations of free
EGF and free PlGF and inactivates their activities (4–11).
urthermore, sFlt-1 forms heterodimers with membrane-
ound Flt-1 (4) and thus acts as a receptor blocker of Flt-1.
hus, sFlt-1 could potentially attenuate the adverse effects
f VEGF and PlGF and may have a beneficial effect in
CS. In fact, a previous report (28) demonstrated that the
igure 3. Comparison of changes in left ventricular ejection fraction
LVEF) from 2 weeks to 6 months after acute myocardial infarction in
atients treated with atorvastatin (n  25) and placebo (n  25).
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July 4, 2006:43–50 Soluble Flt-1 and Statin in Myocardial Infarctionncrease in sFlt-1 plasma levels by its gene transfer inhibited
ascular inflammation and prevented subsequent atheroscle-
osis in an animal model. On the other hand, previous
eports (5,29) using an animal model showed that exoge-
ous administration of sFlt-1 acutely induced hypertension
nd nephrotoxicity probably owing to inhibition of the
ndothelial protective action of endogenous VEGF. How-
ver, the sFlt-1 plasma levels exogenously administered
ere nearly 10 or 100 times higher than the physiologic
lasma levels in these animal experiments (5,29). Further-
igure 4. Correlations between percent changes in LVEF and in plasma
evels of sFlt-1, free VEGF, or free PlGF from 2 weeks to 6 months after
cute myocardial infarction in patients treated with atorvastatin (n  25;
olid circles) and placebo (n  25; open circles). Abbreviations as in
igures 1 and 3.ore, coronary artery disease is a long-term process inumans. Therefore, the role of elevated levels of endoge-
ous sFlt-1 in human atherosclerotic cardiovascular disease
till remains largely unknown.
Soluble Flt-1 has been shown to be expressed in vascular
ndothelium as well as placenta, and alternative splicing has
een identified as a key regulatory step in sFlt-1 production
1–4). Although sFlt-1 expression is increased by hypoxia in
lacenta villous cells (11), the regulatory mechanisms by
hich sFlt-1 levels decreased during the acute phase of MI
n the present study and thereafter increased in response to
torvastatin treatment remain unknown.
There is a marked difference in either total or free levels
f VEGF levels among the different immunodetection
ssays (19). It is known that the measured values are
onsiderably influenced by many factors, including charac-
eristics of the calibrator and specificity of antibodies used in
he assays (19). As shown in Figures 1B and 1D, it is
xpected that total VEGF levels are higher than free VEGF
evels. However, the magnitude of the difference between
otal and free VEGF levels should be carefully interpreted
ecause of differences in characteristics of antibodies to
EGF, calibrators, and immunoassay systems, i.e., compet-
tive binding assay and sandwich ELISA. The PlGF levels
t the chronic phase of MI in the present study were
omparable with the levels in a previous report (30), but the
evels were higher than those in another report (14). The
eason for the difference in PlGF levels among the studies
emains unclear, but it can not be excluded that racial
ifferences or other medications in addition to statin may
ffect PlGF levels.
In conclusion, there was a reciprocal relationship between
hanges in sFlt-1 levels and free VEGF and PlGF levels
fter MI; atorvastatin increased sFlt-1 levels while decreas-
ng free VEGF and PlGF levels. These changes were
ssociated with late improvement of ventricular function
fter AMI, and may represent an additional benefit of statin
herapy.
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